Valuing pre-revenue pipelines with risk-adjusted NPV

Why standard DCFDCFDiscounted Cash Flow (DCF) is a valuation method that estimates an asset's value by projecting future cash flows and discounting them to present value using a required rate of return.View full definition → breaks in biotech

A traditional discounted cash flowdiscounted cash flowDiscounted Cash Flow (DCF) is a valuation method that estimates an asset's value by projecting future cash flows and discounting them to present value using a required rate of return.View full definition → (DCFDCFDiscounted Cash Flow (DCF) is a valuation method that estimates an asset's value by projecting future cash flows and discounting them to present value using a required rate of return.View full definition →) model assumes the product will reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → the market. That is a fine assumption for a soft drink. It is a terrible one for a drug.

Most drugs fail. Only a small fraction of compounds that enter human trials ever get approved. If you run a plain DCFDCFDiscounted Cash Flow (DCF) is a valuation method that estimates an asset's value by projecting future cash flows and discounting them to present value using a required rate of return.View full definition → on peak sales that assume approval, you will wildly overvalue the asset.

rNPV fixes this by inserting one crucial variable: the probability of success (PoS), also called the likelihood of approval. It multiplies each future cash flow by the chance the drug actually gets that far.

rNPV in one sentence: it is a DCFDCFDiscounted Cash Flow (DCF) is a valuation method that estimates an asset's value by projecting future cash flows and discounting them to present value using a required rate of return.View full definition → where every cash flow is weighted by the cumulative probability that the drug survives all remaining clinical and regulatory hurdles.

The clinical stages you are pricing

Before numbers, know the gauntlet. A drug moves through defined phases, and each carries its own historical success rate.

• Preclinical: lab and animal testing before humans.
• Phase I: small trial, mainly checking safety.
• Phase II: larger trial, testing whether the drug actually works (efficacy) and finding the right dose. This is where our asset sits.
• Phase III: large, expensive confirmatory trials.
• Regulatory review: submission to an agency such as the FDA (US Food and Drug Administration) or EMA (European Medicines Agency) for approval.

Each stage has a transition probability: the chance of advancing to the next stage. Multiply the transition probabilities from your current stage to launch, and you get the cumulative PoS.

Oncology (cancer drugs) is notorious for low success rates. Widely cited industry studies, including work summarized by BIO's Clinical Development Success Rates report, estimate that the likelihood of approval from Phase II for oncology assets is in the low single digits to low double digits in percentage terms. Treat any single number as an estimate; rates vary by tumor type, mechanism, and data source.

🎬 [VIDEO: "Risk-Adjusted NPVNPVNet Present Value is the sum of an investment's future cash flows discounted to today, minus the initial outlay. A positive NPV signals value creation.View full definition → (rNPV) for Biotech Valuation" — https://www.youtube.com/results?search_query=risk+adjusted+NPVNPVNet Present Value is the sum of an investment's future cash flows discounted to today, minus the initial outlay. A positive NPV signals value creation.View full definition →+biotech+valuation — a walkthrough of how probability weighting reshapes a drug's DCFDCFDiscounted Cash Flow (DCF) is a valuation method that estimates an asset's value by projecting future cash flows and discounting them to present value using a required rate of return.View full definition →]

Building the model: a Phase II oncology asset

Let us construct one. All figures below are illustrative teaching inputs, not market data.

Step 1: Estimate peak sales

Start with the commercial ceiling. Size it bottom-up:

• Eligible patient population (incidence or prevalence of the cancer, narrowed to the treatable subset).
• Expected market sharemarket shareThe percentage of total industry sales your company captures in a given period. It measures competitive position relative to rivals in a defined market.View full definition → at peak.
• Annual price per patient (net of rebates and discounts).

Say our drug targets a cancer with 40,000 addressable patients per year, reaches 25 percent peak share, at a net price of 120,000 dollars per patient per year.

Peak sales = 40,000 × 0.25 × 120,000 = 1.2 billion dollars per year.

Step 2: Build the revenue curve over the patent window

Drugs do not hit peak sales on day one. They ramp up over several years, plateau, then fall off a cliff when patent protection expires and generic or biosimilar competition enters (the "patent cliff").

Assume launch in year 8 (after Phase II, Phase III, and review), a ramp to peak by year 12, plateau, then erosion after loss of exclusivity around year 20.

Step 3: Subtract costs

Model the outflows:

• R&D costs for remaining Phase III trials (oncology Phase III can run into hundreds of millions of dollars).
• Cost of goods sold (COGS), often modest for small molecules, higher for complex biologics.
• SG&A, the sales force and marketing to launch the drug.

The result is a stream of unadjusted net cash flows, positive after launch, negative during the trial years.

Step 4: Apply stage-specific probability of success

Here is the heart of it. Our asset is entering Phase II. To reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → market it must clear:

• Phase II to Phase III transition
• Phase III to regulatory submission
• Regulatory review to approval

Suppose (illustrative) transition probabilities:

| Stage transition | Probability |

|---|---|

| Phase II → Phase III | 40% |

| Phase III → submission | 55% |

| Submission → approval | 85% |

Cumulative PoS = 0.40 × 0.55 × 0.85 = 0.187, or about 19 percent.

Now apply the weighting. Costs and revenues are treated differently:

• Revenues are multiplied by the full cumulative PoS to launch, because you only earn them if the drug is approved.
• Trial costs are weighted by the probability of reaching that stage. You only pay for Phase III if you actually start it, so weight Phase III costs by the Phase II success probability, and so on.

This asymmetry matters. It prevents you from penalizing near-term, high-probability spending as heavily as far-off, low-probability revenue.

Step 5: Discount to present value

Take each risk-adjusted annual cash flow and discount it using a rate that reflects the time value of money and residual risk. Biotech discount rates are commonly higher than for mature firms; early-stage assets often use rates in the low to mid teens as a percentage, though this is a judgment call, not a fixed rule.

rNPV = sum over all years of:

(risk-adjusted cash flow in year t) / (1 + discount rate) ^ t

A simple way to express the per-year logic:

If the sum is positive, the risk-adjusted asset creates value at today's price. If negative, the market may be paying too much, or your assumptions are too conservative.

Reading and stress-testing the output

A single rNPV number is a starting point, not gospel. The inputs carry huge uncertainty, so the discipline is in testing them.

Sensitivity analysis

Change one variable at a time and watch rNPV move. In most oncology models, the value is most sensitive to:

1. Probability of success. Move Phase II success from 40 to 30 percent and the whole valuation drops sharply, because PoS compounds across stages.

2. Peak sales. Driven by share and price, both of which are contested assumptions.

3. Discount rate. A few points changes long-dated cash flows dramatically.

Show these as a tornado chart or a simple table. Decision-makers trust a range more than a false-precision point estimate.

What rNPV cannot capture

rNPV assumes a single, linear path. It ignores optionality: the ability to abandon a failing program early, or expand into new indications if data are strong. For that, some teams layer on real options analysis. But rNPV remains the defensible baseline that dealmakers, licensing teams, and equity analysts expect to see.

Where the PoS numbers come from

Do not invent success rates. Anchor them in published benchmarks and adjust for your asset's specifics: mechanism of action, biomarker strategy, and trial design. Datasets from industry bodies and academic reviews give stage-by-stage rates by therapeutic area. Oncology sits near the bottom; some rare disease and well-validated targets sit higher.

This lesson is educational and not investment advice. Real valuations demand primary data, clinical input, and professional review.

Key Takeaways

• rNPV = DCF plus probability weighting. Every future cash flow is multiplied by the cumulative chance the drug survives all remaining hurdles, which is essential because most drugs fail.
• Weight revenues and costs differently. Revenues use full cumulative PoS to launch; each stage's trial costs use the probability of reaching that stage.
• PoS compounds, so it dominates the model. For a Phase II oncology asset, multiplying three modest transition probabilities can yield a cumulative success chance below 20 percent.
• Anchor inputs in real benchmarks, then stress-test. Use published stage-specific rates, run sensitivity analysis on PoS, peak sales, and discount rate, and present a range rather than a single number.
• Know the limits. rNPV ignores managerial optionality and assumes a linear path, so treat it as a defensible baseline, not a final answer.